Markl Moster News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Are clinical trials a viable option when no other treatment is bringing results? When her vision suddenly deteriorated, one woman had to make that decision

Press release content from Business Wire. The AP news staff was not involved in its creation. GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye May 3, 2021 GMT Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) PARIS--(BUSINESS WIRE)--May 3, 2021-- Regulatory News: Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Busi...

New data shows encouraging results for patients with neuro-degenerative blinding eye disease New data published in the Journal Science Translational Medicine shows encouraging results in a worldwide clinical trial for patients diagnosed with the neuro-degenerative blinding eye disease; Leber Hereditary Optic Neuropathy (LHON.) The disease is an inherited form of vision loss estimated to affect 1 in 30,000 to 50,000 individuals. LHON most often afflicts people with rapid onset of blindness in the prime of their life - men and women in their teens or twenties. Males are about four to five time...

GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine Non-human primate study clarifies mechanism behind contralateral effect Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal Science Translational Medicine has published results from the ...